IP Library › Granted Patent US 9,127,272
Granted Patent B2
US 9,127,272 · App. 13/353,114 · Granted Sep 8, 2015

Oligomeric compounds and compositions for the use in modulation of target nucleic acids

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,127,272
App. No.
13/353,114
Granted
Sep 8, 2015
Kind
B2
Abstract

Compounds, compositions and methods are provided for modulating the levels expression, processing and function of miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and miRNAs. The oligomeric compounds possess potent miRNA inhibitory activity, and further exhibit improved therapeutic index. Further provided are methods for selectively modulating miRNA activing in a cell.

Claims (9)

1. A single-stranded oligomeric compound comprising a contiguous sequence of 17 to 29 nucleosides linked by internucleoside linking groups, said sequence having an internal region located between two external regions, each external region independently comprises from 1 to 3 nucleosides, each external region comprises only 2′-O(CH 2 ) 2 OCH 3 modified nucleosides, and the internal region comprises only β-D-2′-deoxy-2′-fluororibofuranosyl nucleosides, wherein the compound is complementary to a nucleic acid target that is not a miRNA.

2. The oligomeric compound of claim 1 , where at least one internucleoside linkage group is a phosphorothioate internucleoside linkage group.

3. The oligomeric compound of claim 1 , wherein each internucleoside linkage group is a phosphorothioate internucleoside linkage group.

4. The oligomeric compound of claim 1 , wherein each external region consists of 2 nucleosides and the internal region consists of 19 nucleosides.

5. The oligomeric compound of claim 1 , wherein each external region consists of 2 nucleosides and the internal region consists of 18 nucleosides.

6. The oligomeric compound of claim 1 , wherein each external region consists of 2 nucleosides and the internal region consists of 17 nucleosides.

7. The oligomeric compound of claim 1 , wherein each external region comprises 2 or 3 nucleosides.

8. The oligomeric compound of claim 1 , wherein a first external region comprises 1 or 2 nucleosides and a second external region comprises 2 to 3 nucleosides.

9. The oligomeric compound of claim 1 , wherein the compound is an alternate splicer.

Assignments (1)
CHANGE OF NAME Recorded Jun 15, 2017
From: ISIS PHARMACEUTICALS, INC.
To: IONIS PHARMACEUTICALS, INC.
Reel/Frame 042821/0362 →